乌苯美司联合奥沙利铂和替吉奥治疗晚期胃癌的疗效及对患者免疫功能的影响

Clinical effects of ubeinmex combined with oxaliplatin and S-1 on immune function of patients with advanced gastric cancer

目的:研究乌苯美司联合奥沙利铂和替吉奥在晚期胃癌治疗中的临床疗效和对患者免疫功能的影响。方法:选取2016年01月01日至2018年01月01日蚌埠医学院第一附属医院收治的80例晚期胃腺癌患者,随机分为观察组和对照组,每组40例。两组患者均给予奥沙利铂和替吉奥化疗,观察组患者加用乌苯美司口服。观察两组患者临床疗效、免疫功能以及观察组的疗效与CD13表达的相关性。结果:治疗后观察组患者外周血中CD3^(+)、CD4^(+)T细胞的数量和NK细胞活性增高,CD4^(+)/CD8^(+)比值显著升高,差异有统计学意义(P<0.05);治疗后治疗组和对照组疾病控制率(DCR)分别为77.50%和70.00%,差异有统计学意义(P<0.05);中位无进展生存期(PFS)分别为6.6月和5.7月,差异有统计学意义(P<0.05);总生存期(OS)分别为11.9月和11.6月,差异无统计学意义(P>0.05);进一步研究分析观察组患者OS与CD13的高表达呈正相关(P<0.05)。结论:乌苯美司联合化疗能提高晚期胃腺癌患者的机体免疫功能和患者的无进展生存时间。

Objective:To observe the clinical effects of ubeinmex combined with oxaliplatin and S-1 on immune function of patients with advanced gastric cancer.Methods:80 patients with advanced gastric adenocarcinoma were collected from January 1,2016 to January 1,2018 in the First Affiliated Hospital of Bengbu Medical College and were randomly divided into two groups equally.Two groups of patients were given oxaliplatin and S-1 chemotherapy,and the observation group was treated with ubeinmex.The clinical efficacy and immune function of the two groups were observed,and the correlation between the efficacy and the expression of CD13 was observed in the observation group.Results:After treatment,the number of CD3^(+),CD4^(+)T cells and the activity of NK cell and the ratio of CD4^(+)/CD8^(+)in peripheral blood of the observation group were significantly increased(P<0.05).After treatment,the disease control rate(DCR)of the two groups were 77.50%and 70.00%,respectively.The difference was statistically significant(P<0.05).The median progression-free period(PFS)was 6.6 months and 5.7 months,respectively.The difference was statistically significant(P<0.05).The total survival time(OS)was 11.9 months and 11.6 months,respectively.There was no significant difference between the two groups(P>0.05).The OS in the observation group was positively correlated with the high expression of CD13(P<0.05).Conclusion:Ubenmex combined with chemotherapy can improve the immune function of patients with advanced gastric adenocarcinoma and improve their progression-free survival.